Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 28, 2011

View Archived Issues

Data disclosed from several trials assessing velaglucerase alfa in type 1 Gaucher's disease

Basilea Pharmaceutica discloses more findings from first-in-human trial of BAL-30072

CHMP issues opinion on new indication for Avastin

CHMP recommends approval of Prevanar 13 for new indication

Amarin submits NDA for AMR-101

Biotie to acquire Newron

Two Novartis products approved in Japan

Taliglucerase alfa assessed in Gaucher's disease under French AUT program

Phase I/II trial investigates polyepitope DNA vaccine in metastatic melanoma

Progenics discloses preclinical data on humanized MAbs targeting C. difficile toxins

GSK presents new ITK/TSK inhibitors

Novel tachykinin NK3 receptor antagonists disclosed by Lundbeck

Boehringer Ingelheim prepares novel cannabinoid CB2 receptor agonists

Concert Pharmaceuticals presents novel deuterated compounds

New cathepsin S inhibitors synthesized

Extended-release depot formulation of ropivacaine developed by Encore Therapeutics

Promising results reported on Circassia's ToleroMune Grass hay fever vaccine

Novo Nordisk files MAAs and plans NDA for insulin products

Phase I trial of RNAi therapeutic begins in U.K.

Patient enrollment begins in phase III Wilate study

Glycopyrrolate formulations show efficacy in randomized phase II trials in COPD

Photocure and Ipsen to commercialize Hexvix

CytRx to increase enrollment in INNO-206 clinical trial

Collegium Pharmaceutical and FDA meet regarding phase III COL-003 program

Resverlogix set to begin enrollment in ASSURE study

Abbott Japan and Eisai set to launch new adalimumab formulation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...